Henry Schein (NASDAQ:HSIC) Given New $92.00 Price Target at JPMorgan Chase & Co.

Henry Schein (NASDAQ:HSIC) had its price objective increased by JPMorgan Chase & Co. from $78.00 to $92.00 in a report issued on Wednesday,Benzinga reports. The firm currently has an overweight rating on the stock.

A number of other equities analysts have also recently commented on HSIC. Leerink Partners boosted their price target on Henry Schein from $75.00 to $87.00 and gave the stock a “market perform” rating in a report on Tuesday. Barclays assumed coverage on Henry Schein in a research report on Monday, December 8th. They issued an “overweight” rating and a $86.00 target price for the company. Evercore boosted their price target on Henry Schein from $83.00 to $90.00 and gave the stock an “outperform” rating in a report on Wednesday, November 5th. Wells Fargo & Company raised their price objective on shares of Henry Schein from $76.00 to $87.00 and gave the company an “equal weight” rating in a report on Wednesday. Finally, Mizuho boosted their target price on shares of Henry Schein from $81.00 to $88.00 and gave the stock a “neutral” rating in a report on Wednesday. Six equities research analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $85.58.

Henry Schein Trading Down 1.8%

Shares of HSIC stock opened at $81.87 on Wednesday. The company has a market capitalization of $9.64 billion, a PE ratio of 25.04, a price-to-earnings-growth ratio of 2.48 and a beta of 0.88. The firm has a 50 day moving average price of $77.66 and a two-hundred day moving average price of $71.97. The company has a quick ratio of 0.79, a current ratio of 1.38 and a debt-to-equity ratio of 0.59. Henry Schein has a 12-month low of $60.56 and a 12-month high of $89.29.

Henry Schein (NASDAQ:HSIC) last posted its earnings results on Tuesday, February 24th. The company reported $1.34 earnings per share for the quarter, topping analysts’ consensus estimates of $1.30 by $0.04. Henry Schein had a return on equity of 15.16% and a net margin of 3.02%.The company had revenue of $3.44 billion during the quarter, compared to the consensus estimate of $3.34 billion. During the same quarter last year, the firm earned $1.19 earnings per share. The company’s revenue was up 7.7% on a year-over-year basis. Henry Schein has set its FY 2026 guidance at 5.230-5.370 EPS. As a group, analysts predict that Henry Schein will post 4.74 earnings per share for the current year.

Institutional Investors Weigh In On Henry Schein

A number of institutional investors have recently modified their holdings of HSIC. Ameriprise Financial Inc. raised its stake in Henry Schein by 3,275.2% during the second quarter. Ameriprise Financial Inc. now owns 2,266,858 shares of the company’s stock worth $165,594,000 after buying an additional 2,199,695 shares during the last quarter. Bank of Montreal Can boosted its position in Henry Schein by 3,655.7% during the fourth quarter. Bank of Montreal Can now owns 2,144,773 shares of the company’s stock valued at $162,102,000 after acquiring an additional 2,087,666 shares during the last quarter. Norges Bank acquired a new stake in Henry Schein during the 2nd quarter worth about $89,476,000. M.D. Sass LLC bought a new stake in shares of Henry Schein during the 2nd quarter valued at about $79,201,000. Finally, Schroder Investment Management Group grew its position in shares of Henry Schein by 149.3% during the 2nd quarter. Schroder Investment Management Group now owns 1,563,899 shares of the company’s stock worth $114,243,000 after buying an additional 936,471 shares during the period. 96.62% of the stock is owned by institutional investors.

More Henry Schein News

Here are the key news stories impacting Henry Schein this week:

• Positive Sentiment: Company beat Q4 estimates on both EPS and revenue (Q4 EPS $1.34 vs $1.30 est.; revenue $3.44B vs $3.34B) and gave FY‑2026 EPS and revenue guidance roughly in line with consensus — a core driver of the recent rally. Article Title Press Release
• Positive Sentiment: Several brokers raised price targets or upgraded the stock after the earnings beat: JPMorgan to $92 (Overweight), Robert W. Baird upgraded to Outperform with a $100 target, UBS, Mizuho, Wells Fargo and Leerink also lifted targets into the mid‑$80s–$100 range — supporting upside expectations. Benzinga roundup TickerReport
• Positive Sentiment: Market momentum: the shares recently hit a 52‑week high as investors re‑rated growth from equipment, specialty and tech segments after the call. MSN article
• Neutral Sentiment: FY‑2026 guidance was close to Street expectations (EPS 5.23–5.37 vs consensus ~5.28; revenue $13.6–13.8B vs ~$13.5B), which reduces surprise risk but doesn’t materially raise the bar for beat-and-raise momentum. Press Release
• Negative Sentiment: Margin pressures flagged on the call and in analyst notes — revenue growth was strong but margins contracted, which some analysts cite as a reason to temper enthusiasm and cap multiple expansion. Zacks margin note
• Negative Sentiment: Not all analysts turned positive — Morgan Stanley (Erin Wright) maintained a sell/underweight stance with a much lower $58–$61 price target, and some investors may have taken profits or remained cautious because of valuation vs. margin risk. TipRanks Benzinga note

About Henry Schein

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.